U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO ZAI LAB’S DLL3-TARGETING ADC ZOCILURTATUG PELITECAN (ZOCI) FOR THE TREATMENT OF NEUROENDOCRINE CARCINOMAS (NECS)

Reuters · 2d ago

Please log in to view news